Towards establishing the standard of care for second-line therapy in advanced biliary tract cancer

Affiliations

Comment

Eliza W Beal. Lancet Oncol. 2021 Nov.

. 2021 Nov;22(11):1488-1490.

doi: 10.1016/S1470-2045(21)00543-X. Epub 2021 Oct 14.

¹ The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Electronic address: eliza.beal@osumc.edu.

No abstract available

Conflict of interest statement

I declare no competing interests.

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, Kang BW, Ryu H, Lee JS, Kim KW, Abou-Alfa GK, Ryoo BY. Yoo C, et al. Lancet Oncol. 2021 Nov;22(11):1560-1572. doi: 10.1016/S1470-2045(21)00486-1. Epub 2021 Oct 14. Lancet Oncol. 2021. PMID: 34656226 Clinical Trial.